Market Cap | 549.48K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -189.82k | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 13.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 16.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -61.00% |
Recommedations | - | Quick Ratio | 0.10 | Shares Outstanding | 804.64M | 52W Low Chg | 150.00% |
Insider Own | 55.30% | ROA | -65.04% | Shares Float | - | Beta | 1.62 |
Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.00075 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 3,999,878 | Target Price | - |
Oper. Margin | - | Earnings Date | - | Volume | 3,334,806 | Change | -6.25% |
The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics. It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body. The company has a license agreement with Shaare Zedek Scientific Ltd. that focuses on treatment of autism, schizophrenia, Parkinson's disease, Alzheimer's disease, and other neuropsychiatric disorders. The Greater Cannabis Company, Inc. was founded in 2014 and is based in Baltimore, Maryland.